CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

Core Insights - CorMedix Inc. is set to report its financial results for Q4 and the full year of 2024 on March 25, 2025, before market opening [1] - The company will host a corporate update conference call at 8:30 AM ET on the same day [2] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [3] - The company's lead product, DefenCath® (taurolidine and heparin), received FDA approval on November 15, 2023, and was commercially launched in inpatient settings in April 2024 and outpatient settings in July 2024 [3] - CorMedix plans to commence clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patients in 2025, and aims to develop DefenCath as a catheter lock solution for other therapeutic areas [3]